Brain cancer vaccine - Immune Response

Drug Profile

Brain cancer vaccine - Immune Response

Alternative Names: IR 850

Latest Information Update: 09 Nov 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Brain cancer

Most Recent Events

  • 09 Sep 2004 Immune Response Corporation has signed a licensing transfer agreement with NovaRx covering rights in-licensed from the Sidney Kimmel Cancer Center
  • 31 Dec 2003 Discontinued - Phase-I for Brain cancer in USA (Intradermal)
  • 25 Jun 2002 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top